Citadel Advisors
TRDA icon

Citadel Advisors’s Entrada Therapeutics TRDA Stock Holding History

Citadel Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Buy
394,323
+179,305
+83% +$1.72M ﹤0.01% 5765
2026
Q1 		$2.71M Sell
215,018
-77,752
-27% -$891K ﹤0.01% 5465
2025
Q4 		$3.01M Sell
292,770
-42,971
-13% -$362K ﹤0.01% 5152
2025
Q3 		$1.95M Buy
335,741
+235,384
+235% +$1.38M ﹤0.01% 6121
2025
Q2 		$674K Buy
100,357
+83,904
+510% +$675K ﹤0.01% 7925
2025
Q1 		$149K Sell
16,453
-54,216
-77% -$676K ﹤0.01% 10887
2024
Q4 		$1.22M Sell
70,669
-17,555
-20% -$318K ﹤0.01% 6617
2024
Q3 		$1.41M Sell
88,224
-42,225
-32% -$665K ﹤0.01% 6180
2024
Q2 		$1.86M Buy
130,449
+60,773
+87% +$864K ﹤0.01% 5451
2024
Q1 		$987K Buy
+69,676
New +$985K ﹤0.01% 6938
2022
Q3 		– Sell
-12,947
Closed -$158K – 13624
2022
Q2 		$158K Sell
12,947
-51,452
-80% -$390K ﹤0.01% 10939
2022
Q1 		$604K Sell
64,399
-44,395
-41% -$476K ﹤0.01% 8939
2021
Q4 		$1.86M Buy
+108,794
New +$2.64M ﹤0.01% 6418

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Citadel Advisors's TRDA Position: Q2 2026 in Review

Citadel Advisors increased its Entrada Therapeutics (TRDA) stake by 83% in Q2 2026, buying an estimated $1.72M and bringing the position to 394,323 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #5765.

Citadel Advisors first reported a position in TRDA in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.01M in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Citadel Advisors held 394,323 shares of Entrada Therapeutics worth $2.9M as of Q2 2026.
  • Citadel Advisors bought 179,305 Entrada Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Entrada Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5765 holding.
  • Citadel Advisors first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Entrada Therapeutics position peaked at $3.01M in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.